Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Pulseless electrical activity? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Pulseless electrical activity have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.

12
Reports of Pulseless electrical activity with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
6
Deaths
9
Hospitalizations

How Dangerous Is Pulseless electrical activity From PEMBROLIZUMAB?

Of the 12 reports, 6 (50.0%) resulted in death, 9 (75.0%) required hospitalization, and 5 (41.7%) were considered life-threatening.

Is Pulseless electrical activity Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Pulseless electrical activity?

METFORMIN (140) PROPRANOLOL (136) BUPROPION (135) OXYCODONE (111) LORAZEPAM (106) PROPOFOL (104) CITALOPRAM HYDROBROMIDE (101) EPINEPHRINE (87) FENTANYL (87) AMLODIPINE (82)

Which PEMBROLIZUMAB Alternatives Have Lower Pulseless electrical activity Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Pulseless electrical activity Reports All Drugs Causing Pulseless electrical activity PEMBROLIZUMAB Demographics